| 38012862 | Wait Time Advantage for Transplant Candidates With HIV Who Accept Kidneys From Donors With HIV Under the HOPE Act. | Transplantation | 2024 |
| 36345608 | Comparison of allocation strategies of convalescent plasma to reduce excess infections and mortality from SARS-CoV-2 in a US-like population. | Transfusion | 2023 |
| 37808671 | HIV incidence among non-migrating persons following a household migration event: a population-based, longitudinal study in Uganda. | medRxiv | 2023 |
| 37529719 | Therapeutic plasma exchange in the management of stiff person syndrome spectrum disorders: a case series and review of the literature. | Ther Adv Neurol Disord | 2023 |
| 37859995 | Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis. | Mayo Clin Proc Innov Qual Outcomes | 2023 |
| 37705364 | Population prevalence of antiretroviral therapy sharing and its association with HIV viremia in rural Uganda: a cross-sectional population-based study. | J Int AIDS Soc | 2023 |
| 37659419 | Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study. | Lancet Microbe | 2023 |
| 37620337 | SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations. | Nat Commun | 2023 |
| 37646070 | Survey of blood collection and transfusion practices among institutions in Africa. | Transfusion | 2023 |
| 37980192 | Blood Demand Forecasting and Supply Management: An Analytical Assessment of Key Studies Utilizing Novel Computational Techniques. | Transfus Med Rev | 2023 |
| 37824153 | Red Blood Cell Transfusion: 2023 AABB International Guidelines. | JAMA | 2023 |
| 37534607 | Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials. | Transfusion | 2023 |
| 37724870 | Early antibody treatment, inflammation, and risk of post-COVID conditions. | mBio | 2023 |
| 35579509 | Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial. | Clin Infect Dis | 2023 |
| 37354908 | Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization. | Cell Chem Biol | 2023 |
| 37255467 | SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022. | Transfusion | 2023 |
| 37214769 | Pediatric firearm injury related emergency department visits and hospitalizations: a population-based study in the United States. | Lancet Reg Health Am | 2023 |
| 36987595 | Coronavirus Disease 2019 Convalescent Plasma Utilization in the United States: Data From the National Inpatient Sample. | Clin Infect Dis | 2023 |
| 37079374 | Age Patterns of HSV-2 Incidence and Prevalence in Two Ugandan Communities: A Catalytic Incidence Model Applied to Population-Based Seroprevalence Data. | J Infect Dis | 2023 |
| 37379584 | HIV-Positive Liver Transplant Does not Alter the Latent Viral Reservoir in Recipients With Antiretroviral Therapy-Suppressed HIV. | J Infect Dis | 2023 |
| 37104041 | Heterologous versus homologous boosting elicits qualitatively distinct, BA.5-cross-reactive T cells in transplant recipients. | JCI Insight | 2023 |
| 37131659 | Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial. | medRxiv | 2023 |
| 36966905 | Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose. | Am J Transplant | 2023 |
| 37129864 | Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19. | Expert Rev Hematol | 2023 |
| 36722044 | Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial. | J Infect Dis | 2023 |
| 36651598 | Patient-reported outcomes after Tixagevimab and Cilgavimab pre-exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk. | Clin Transplant | 2023 |
| 36437691 | 6-month antibody kinetics and durability after four doses of a SARS-CoV-2 vaccine in solid organ transplant recipients. | Clin Transplant | 2023 |
| 36740590 | Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019. | Clin Infect Dis | 2023 |
| 36840443 | Blood donor, component, and recipient-specific factors associated with venous thromboembolism in transfused hospitalized adult patients: Data from the recipient epidemiology and donor evaluation Study-III (REDS-III). | Transfusion | 2023 |
| 36907248 | Impact of expanding HOPE Act experience criteria on program eligibility for transplantation from donors with human immunodeficiency virus to recipients with human immunodeficiency virus. | Am J Transplant | 2023 |
| 36869689 | Trends in Adolescent Human Papillomavirus Vaccination and Parental Hesitancy in the United States. | J Infect Dis | 2023 |
| 36906295 | Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients. | Am J Transplant | 2023 |
| 36637364 | Transfusion-transmitted babesiosis in a patient with sickle cell disease undergoing chronic red cell exchange. | Transfusion | 2023 |
| 36528466 | Eligibility Considerations for Female Whole Blood Donors: Hemoglobin Levels and Iron Status in a Nationally Representative Population. | Transfus Med Rev | 2023 |
| 36824860 | Early Treatment, Inflammation and Post-COVID Conditions. | medRxiv | 2023 |
| 36268708 | Absence of pathogenic viruses in COVID-19 convalescent plasma. | Transfusion | 2023 |
| 34180726 | Barriers experienced by organ procurement organizations in implementing the HOPE act and HIV-positive organ donation. | AIDS Care | 2022 |
| 35352362 | How do I implement an outpatient program for the administration of convalescent plasma for COVID-19? | Transfusion | 2022 |
| 35679259 | Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals. | PLoS One | 2022 |
| 35443020 | Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. | Blood Adv | 2022 |
| 35379302 | The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial. | Trials | 2022 |
| 35670813 | Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses. | Clin Transplant | 2022 |
| 35791054 | Letter to the editor: Six-month antibody kinetics and durability in liver transplant recipients after two doses of SARS-CoV-2 mRNA vaccination. | Hepatol Commun | 2022 |
| 35429211 | Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination. | Am J Transplant | 2022 |
| 35822545 | Immunogenicity of Ad26.COV2.S prime and two subsequent doses of mRNA SARS-CoV-2 vaccines in solid organ transplant recipients: A case series. | Clin Transplant | 2022 |
| 35665017 | Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant Recipients. | medRxiv | 2022 |
| 35426888 | Antibody Response to a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: An Update. | Transplantation | 2022 |
| 35389558 | Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients. | Liver Transpl | 2022 |
| 35417115 | A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. | Transplantation | 2022 |
| 35859275 | Predicting a Positive Antibody Response After 2 SARS-CoV-2 mRNA Vaccines in Transplant Recipients: A Machine Learning Approach With External Validation. | Transplantation | 2022 |